Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02558491 · ClinicalTrials.gov registry record · NA
Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM
A NA study, sponsored by Daniel Chernavvsky, MD.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT02558491: Completed NA study, sponsored by Daniel Chernavvsky, MD.
NCT02558491 is a NA study that has completed, run by Daniel Chernavvsky, MD. The registered enrollment target is 33 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02558491, a NA study, has completed, sponsored by Daniel Chernavvsky, MD.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the safety and feasibility of a decision support system aimed at reducing glucose variability in T1DM patient using an insulin pump.
Primary Outcome
Assess effectiveness of glucose variability (GV) advisory system in reducing glucose variability in T1DM patient using an insulin pump.
Interventions
- OTHER Usual Care
- DEVICE Decision Support System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-02 |
| Phase | NA |
What the finished NCT02558491 record still lists
NCT02558491 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Usual Care is the first listed.
NCT02558491 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02558491 about?
NCT02558491 is a clinical study titled "Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM". The purpose of this study is to demonstrate the safety and feasibility of a decision support system aimed at reducing glucose variability in T1DM patient using an insulin pump.
What is the current status of trial NCT02558491?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2015-09. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02558491?
The interventions under investigation include: Usual Care (OTHER), Decision Support System (DEVICE).
Who is sponsoring clinical trial NCT02558491?
This trial is sponsored by Daniel Chernavvsky, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02558491's enrollment target sits among peer trials
33 1574th of 2000 higher than 423 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia